Does eventually NPM1 mutation in blast phase chronic myeloid leukemia (BP-CML) exist? That is the question

Br J Haematol. 2021 Nov;195(3):469-471. doi: 10.1111/bjh.17761. Epub 2021 Aug 15.
No abstract available

Keywords: NPM1 mutations; blast phase CML; dasatinib.

Publication types

  • Letter

MeSH terms

  • Algorithms
  • Antineoplastic Agents / therapeutic use
  • Basophils / pathology
  • Blast Crisis / genetics*
  • Dasatinib / therapeutic use
  • Diagnosis, Differential
  • Fusion Proteins, bcr-abl / genetics
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation, Missense*
  • Neoplasm Proteins / genetics*
  • Nucleophosmin / genetics*
  • Philadelphia Chromosome
  • Protein Kinase Inhibitors / therapeutic use
  • Sarcoma, Myeloid / etiology

Substances

  • Antineoplastic Agents
  • NPM1 protein, human
  • Neoplasm Proteins
  • Protein Kinase Inhibitors
  • Nucleophosmin
  • Fusion Proteins, bcr-abl
  • Dasatinib